Liu J - Search Results

1

Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database.

Hu H, Fu Z, Liu J, Zhang C, Li S, Zhang Y, You R. Hu H, et al. Among authors: liu j. Front Pharmacol. 2024 Jun 24;15:1339505. doi: 10.3389/fphar.2024.1339505. eCollection 2024. Front Pharmacol. 2024. PMID: 38978981 Free PMC article.

2

Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer.

Fu Z, Li S, Liu J, Zhang C, Jian C, Wang L, Zhang Y, Shi C. Fu Z, et al. Among authors: liu j. Front Pharmacol. 2022 Mar 15;13:847906. doi: 10.3389/fphar.2022.847906. eCollection 2022. Front Pharmacol. 2022. PMID: 35370661 Free PMC article.

3

Fu Z, Liu J, Zhang C, Hu H, Li S, Zhang Y, You R. Fu Z, et al. Among authors: liu j. Front Pharmacol. 2024 Jun 14;15:1383212. doi: 10.3389/fphar.2024.1383212. eCollection 2024. Front Pharmacol. 2024. PMID: 38948476 Free PMC article.

4

Fu Z, Liu J, Li S, Shi C, Zhang Y. Fu Z, et al. Among authors: liu j. EClinicalMedicine. 2022 Dec 27;55:101795. doi: 10.1016/j.eclinm.2022.101795. eCollection 2023 Jan. EClinicalMedicine. 2022. PMID: 36712893 Free PMC article.

5

Corrigendum to "Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis" [EClinicalMedicine 55 (2022) 101795].

Fu Z, Liu J, Li S, Shi C, Zhang Y. Fu Z, et al. Among authors: liu j. EClinicalMedicine. 2023 Mar 16;58:101908. doi: 10.1016/j.eclinm.2023.101908. eCollection 2023 Apr. EClinicalMedicine. 2023. PMID: 36969339 Free PMC article.

6

Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data.

Shi C, Wang X, Diao C, Zhu H, Yuan Q, Liu J, Li S, Gu M, Zhang Y. Shi C, et al. Among authors: liu j. Drug Des Devel Ther. 2021 May 20;15:2151-2159. doi: 10.2147/DDDT.S305792. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34045849 Free PMC article.

7

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations.

Shi C, Zhang C, Fu Z, Liu J, Zhou Y, Cheng B, Wang C, Li S, Zhang Y. Shi C, et al. Among authors: liu j. Acta Pharm Sin B. 2023 Jun;13(6):2613-2627. doi: 10.1016/j.apsb.2023.03.007. Epub 2023 Mar 10. Acta Pharm Sin B. 2023. PMID: 37425047 Free PMC article.

8

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway.

Shi C, Wang C, Fu Z, Liu J, Zhou Y, Cheng B, Zhang C, Li S, Zhang Y. Shi C, et al. Among authors: liu j. Pharmacol Res. 2024 Mar;201:107088. doi: 10.1016/j.phrs.2024.107088. Epub 2024 Feb 1. Pharmacol Res. 2024. PMID: 38295916 Free article.

9

Practice, Knowledge, and Attitude of Health Care Providers regarding Cancer Pain Management: A National Survey.

Liu J, Zhang M, Luo J, Xie J, Chen X, Wang H, Li S, Yang S, Peng C, Yang L, Deng B, Zhang Y, Wang C, Hu J, Shi C. Liu J, et al. Pain Res Manag. 2021 Aug 23;2021:1247202. doi: 10.1155/2021/1247202. eCollection 2021. Pain Res Manag. 2021. PMID: 34471442 Free PMC article.

10

Application of Quality Control Circle Activity in Improving Effectiveness of Drug Intervention in Lung Cancer Patients with Moderate to Severe Pain.

Gu M, Hua XL, Li SJ, Luo J, Liu JM, Zhang Y, Shi C. Gu M, et al. Among authors: liu jm. Curr Med Sci. 2021 Oct;41(5):996-1003. doi: 10.1007/s11596-021-2451-x. Epub 2021 Oct 15. Curr Med Sci. 2021. PMID: 34661813

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143,933 results

Search Page

Filters